Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Holdings Lessened by Squarepoint Ops LLC

Squarepoint Ops LLC trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 22.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,421 shares of the company's stock after selling 8,703 shares during the period. Squarepoint Ops LLC owned 0.10% of Medpace worth $10,107,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its position in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after acquiring an additional 29 shares during the period. Assetmark Inc. boosted its stake in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after purchasing an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. boosted its stake in Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after acquiring an additional 30 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 20.30% of the stock is currently owned by insiders.

Medpace Trading Up 1.1%

Shares of NASDAQ MEDP traded up $3.27 during mid-day trading on Thursday, reaching $297.08. The company had a trading volume of 73,657 shares, compared to its average volume of 352,920. The firm has a 50 day simple moving average of $300.15 and a two-hundred day simple moving average of $325.70. The stock has a market cap of $8.54 billion, a P/E ratio of 23.52, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. During the same period last year, the firm posted $3.20 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of several recent analyst reports. Mizuho lowered their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and lowered their target price for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Finally, Truist Financial lowered their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday, April 23rd. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.